- Home
- IGC vs CYTH Comparison
IGC vs CYTH Comparison
Compare IGC & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- CYTH
- Stock Information
- Founded
- IGC 2005
- CYTH 1990
- Country
- IGC United States
- CYTH United States
- Employees
- IGC N/A
- CYTH N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- IGC Health Care
- CYTH Health Care
- Exchange
- IGC Nasdaq
- CYTH Nasdaq
- Market Cap
- IGC 29.4M
- CYTH 31.9M
- IPO Year
- IGC N/A
- CYTH N/A
- Fundamental
- Price
- IGC $0.31
- CYTH $0.68
- Analyst Decision
- IGC Strong Buy
- CYTH Buy
- Analyst Count
- IGC 2
- CYTH 3
- Target Price
- IGC $3.88
- CYTH $0.95
- AVG Volume (30 Days)
- IGC 392.1K
- CYTH 150.3K
- Earning Date
- IGC 02-18-2025
- CYTH 03-21-2025
- Dividend Yield
- IGC N/A
- CYTH N/A
- EPS Growth
- IGC N/A
- CYTH N/A
- EPS
- IGC N/A
- CYTH N/A
- Revenue
- IGC $1,236,000.00
- CYTH $870,725.00
- Revenue This Year
- IGC N/A
- CYTH N/A
- Revenue Next Year
- IGC $18.34
- CYTH $24.49
- P/E Ratio
- IGC N/A
- CYTH N/A
- Revenue Growth
- IGC 1.64
- CYTH N/A
- 52 Week Low
- IGC $0.26
- CYTH $0.55
- 52 Week High
- IGC $0.91
- CYTH $1.79
- Technical
- Relative Strength Index (RSI)
- IGC 52.84
- CYTH 39.14
- Support Level
- IGC $0.26
- CYTH $0.85
- Resistance Level
- IGC $0.34
- CYTH $0.80
- Average True Range (ATR)
- IGC 0.02
- CYTH 0.07
- MACD
- IGC 0.01
- CYTH -0.02
- Stochastic Oscillator
- IGC 65.88
- CYTH 0.00
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.